Investment Rating - The report maintains an investment rating of "Outperform the Market - B" for the construction industry [4]. Core Insights - The construction industry is currently under pressure, with revenue and net profit declining year-on-year. However, there are expectations for policy support and investment increases, particularly in infrastructure, which may improve the industry's fundamentals [17][18]. - The report highlights the potential for significant investment demand driven by urbanization and infrastructure upgrades, estimating a need for approximately 4 trillion yuan in investment over the next five years for urban underground pipeline renovations [16]. - The report suggests focusing on traditional state-owned enterprises in construction, which are currently undervalued and may benefit from improved financial metrics and increased infrastructure spending [11][12]. Summary by Sections Industry Dynamics Analysis - The construction sector is facing operational challenges in 2024 and Q1 2025, with revenue and net profit both experiencing year-on-year declines of 3.89% and 15.98% respectively in 2024, and 6.27% and 8.54% in Q1 2025 [17][19]. - The report emphasizes the importance of expanding domestic demand as a key support for economic growth amid external pressures such as tariffs from the U.S. [17]. Market Performance - The construction and decoration industry saw a decline of 1.26% in the week from April 28 to April 30, underperforming compared to major indices [46]. - The report notes that while the overall industry is struggling, certain segments like landscaping engineering have shown positive performance [46]. Company Announcements - The report includes a summary of major order announcements from companies within the industry, indicating ongoing activity despite the challenging environment [58]. Key Focus Stocks - The report identifies several key stocks to watch, including major state-owned construction firms and companies involved in infrastructure design and international engineering services, which are expected to benefit from increased investment and policy support [11][12][57].

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 9.08 CNY, compared to the current stock price of 7.81 CNY as of April 30, 2025 [5]. Core Views - The company's Q1 2025 revenue was 256.76 billion CNY, a year-on-year decrease of 6.61%, primarily due to weak demand in traditional business sectors. The net profit attributable to shareholders was 5.15 billion CNY, down 14.51% year-on-year, with a decline in gross margin contributing to the profit drop [2][3]. - Despite the revenue and profit decline, the company has a solid order backlog of 7.86 trillion CNY, approximately 7.4 times its 2024 revenue, indicating a strong foundation for future revenue growth [2]. - The company signed new contracts worth 492.84 billion CNY in Q1 2025, with a notable increase in overseas contracts by 30.10% year-on-year, while domestic contracts decreased by 13.17% [4]. Summary by Sections Financial Performance - In Q1 2025, the company experienced a gross margin decline of 0.28 percentage points, leading to a sales net profit margin of 2.38%, down 0.20 percentage points year-on-year. The operating cash flow improved, with a net outflow of 38.95 billion CNY, which is 7.65 billion CNY less than the previous year [2][3]. Order and Contract Activity - The new contract value in Q1 2025 was 492.84 billion CNY, with domestic contracts at 448.68 billion CNY and overseas contracts at 44.16 billion CNY. The growth in the green environmental sector and railway engineering contracts was particularly strong, with increases of 77.05% and 66.25% year-on-year, respectively [4]. Earnings Forecast - The company’s revenue projections for 2025-2027 are 1.08 trillion CNY, 1.10 trillion CNY, and 1.11 trillion CNY, with expected year-on-year growth rates of 1.50%, 1.30%, and 1.30%. The net profit forecasts for the same period are 22.47 billion CNY, 22.73 billion CNY, and 22.99 billion CNY, with corresponding growth rates of 1.15% each year [9][10].

Investment Rating - The investment rating for Postal Savings Bank is "Buy-A" with a target price of 6.31 CNY over the next six months [5]. Core Views - The report highlights that the bank's revenue in Q1 2025 decreased by 0.07% year-on-year, while the pre-provision profit grew by 6.20%. However, the net profit attributable to shareholders fell by 2.62% year-on-year. The main drivers for performance were the expansion of interest-earning assets and cost reduction, while narrowing net interest margins and increased provisioning negatively impacted growth [1][11]. Summary by Sections Financial Performance - As of the end of Q1 2025, Postal Savings Bank's total assets grew by 8.31% year-on-year, with total loans increasing by 9.78% and financial investments by 9.45%. The bank added 604.5 billion CNY in total assets and 443 billion CNY in loans during the quarter [1]. - The bank's net interest margin for Q1 2025 was measured at 1.71%, down 21 basis points year-on-year and 10 basis points quarter-on-quarter, but still remains competitive within the industry [4][9]. - Non-interest income increased by 14.83% year-on-year, with net fees growing by 8.76% and investment income rising by 21.70% [10]. Loan Growth - Corporate loans saw a significant increase of 15.17% year-on-year, with a quarterly addition of 362 billion CNY, leading among major banks [2]. - Retail loans grew by 4.27% year-on-year, with a quarterly addition of 678 billion CNY, although this was a decrease compared to previous quarters [2]. Deposit Growth - Total deposits increased by 9.22% year-on-year, with corporate and retail deposits growing by 20.46% and 7.94% respectively. The bank focused on low-cost self-operated deposits, adding 141.7 billion CNY in corporate deposits during the quarter [3]. Asset Quality - The non-performing loan ratio stood at 0.91% at the end of Q1 2025, remaining stable. The provision coverage ratio was 266.13%, indicating a solid buffer against potential loan losses [10][11]. Future Outlook - The bank plans to enhance support for key sectors such as new productivity and inclusive small and micro enterprises, while also increasing consumer loan offerings in response to policy opportunities. The cost advantage on the liability side, combined with adjustments in agency fee rates, is expected to support performance [11].

Investment Rating - The investment rating for Chengdu Bank is "Accumulate-A" with a target price of 18.87 CNY over the next six months [4]. Core Views - Chengdu Bank has demonstrated robust growth in both asset scale and performance, with a revenue growth rate of 5.89% for 2024 and a net profit growth rate of 10.17% [1][9]. - The bank's performance is primarily driven by the expansion of interest-earning assets, although net interest margin compression has been a significant drag on growth in early 2025 [1][8]. - The bank is expected to maintain a stable performance due to its strong asset quality and sufficient provisioning, with projected revenue growth of 8.17% and profit growth of 9.25% for 2025 [9][10]. Summary by Sections Financial Performance - Chengdu Bank's total assets grew by 14.56% year-on-year by the end of 2024, with a quarterly increase of 285 billion CNY, while loans increased by 18.76% year-on-year [1][2]. - In Q1 2025, total assets increased by 13.25% year-on-year, with loans contributing significantly to this growth [1][2]. Loan Growth - Corporate loans showed steady growth, with balances increasing by 20.31% year-on-year by the end of 2024 and 17.69% year-on-year by the end of Q1 2025 [2]. - Retail loans also performed well, with year-on-year growth rates of 12.46% and 13.37% for 2024 and Q1 2025, respectively [3]. Asset Quality - Chengdu Bank maintained a low non-performing loan (NPL) ratio of 0.66% at the end of both 2024 and Q1 2025, indicating strong asset quality [9][10]. - The bank's provisioning coverage ratio was robust at 479.29% by the end of 2024 and 456.00% by the end of Q1 2025, reflecting its strong risk mitigation capabilities [9][10]. Non-Interest Income - Non-interest income showed a significant increase of 24.11% year-on-year in Q4 2024, primarily driven by investment income, although fee income declined [9][10]. Interest Margin - The net interest margin for 2024 was stable at 1.66%, but a significant decline is expected in Q1 2025 due to the impact of interest rate adjustments [8][9]. Future Outlook - The bank is expected to continue focusing on government-related financing while also responding to policy calls to enhance industrial demand and increase technology and green loan offerings in 2025 [2][9].

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 55 CNY, maintaining the rating [4][13]. Core Views - The company's Q1 2025 performance shows a reliance on scale expansion for profit growth, while net interest margin has narrowed and non-interest income growth has slowed [1][12]. - The bank's deposit advantage has strengthened, with a significant increase in interest-bearing liabilities and deposits, supporting future asset expansion [2][12]. - The outlook for net interest margin remains under pressure due to weak effective financing demand, but the bank's strong deposit base is expected to maintain a relatively high level compared to the industry [8][12]. Summary by Sections Financial Performance - In Q1 2025, the company's revenue decreased by 3.09% year-on-year, while net profit attributable to shareholders grew by 2.08% [1]. - The average daily balance of interest-earning assets increased by 8.7% year-on-year, with new interest-earning assets added amounting to 176.6 billion CNY, a year-on-year increase of 8.4 billion CNY [1][18]. Loan and Deposit Structure - New corporate loans grew rapidly, primarily directed towards manufacturing, IT transmission, construction, and public utilities, while retail loan issuance remained weak [2][12]. - The average daily balance of interest-bearing liabilities increased by 8.6% year-on-year, with deposits growing at a rate of 9.4%, significantly outpacing loan growth of 5.2% [2][12]. Net Interest Margin - The net interest margin for Q1 2025 was 1.91%, down 11 basis points year-on-year, primarily due to a decrease in asset yield [3][8]. - The yield on interest-earning assets decreased to 3.21%, with loan yield dropping by 17 basis points [3][8]. Non-Interest Income - Non-interest income from fees and commissions decreased by 2.51% year-on-year, with wealth management income growing by 10.45% [8][12]. - Other non-interest income faced pressure, declining by 22.2% year-on-year due to rising market interest rates affecting bond and fund investments [9][12]. Asset Quality - The bank's non-performing loan ratio slightly decreased to 0.94%, indicating stable asset quality, while the coverage ratio remained robust at around 410% [9][12]. - The non-performing loan generation rate for Q1 2025 was 1%, showing a year-on-year decline of 3 basis points [10][12]. Future Outlook - The bank anticipates a modest revenue growth of 0.61% and a net profit growth of 1.24% for 2025, with expectations of a recovery in the capital market supporting its performance [13][14].

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 32.79 CNY per share [4]. Core Views - The report indicates that the company has seen a recovery in sales, with April wholesale sales reaching 100,000 units, a year-on-year increase of 6% and a month-on-month increase of 2% [2]. - The company is entering a new growth phase, driven by new product launches and improved marketing strategies, which are expected to lead to an upward trend in sales [3]. - The report highlights the potential for significant profit elasticity due to the introduction of new models and advanced technologies [3]. Sales Performance - April sales were boosted by the accelerated delivery of the Tank 300 and the launch of the second-generation Xiaolong MAX, contributing to a year-on-year increase in sales [2]. - The company sold 29,000 new energy vehicles in April, representing a year-on-year increase of 28% and a month-on-month increase of 14% [2]. - The sales breakdown for April includes 57,000 units for Haval (up 21% year-on-year), 4,811 units for Wey (up 8% year-on-year), and 1,797 units for Ora (down 62% year-on-year) [2]. Financial Forecast - The company is projected to achieve net profits of 14.03 billion CNY, 17.40 billion CNY, and 20.96 billion CNY for the years 2025, 2026, and 2027, respectively [9]. - The expected price-to-earnings ratios for these years are 13.8, 11.1, and 9.2 times, indicating a favorable valuation trend [8][9]. - Revenue is forecasted to grow from 173.21 billion CNY in 2023 to 336.49 billion CNY by 2027, reflecting a compound annual growth rate [9][10]. Market Outlook - The mainstream market for new vehicles is expected to see an upward sales trend, supported by the successful launch of new models and enhanced marketing efforts [3]. - The company has a diverse product lineup and strong technological reserves, which position it well for future growth in both domestic and international markets [3]. - The report emphasizes the potential for the Hi4Z technology to expand the company's market share in the off-road segment, enhancing profitability [3].

Investment Rating - The investment rating for the company is "Buy-A" with a target price of HKD 135.84, which corresponds to a PE ratio of 26x for 2025 [7]. Core Views - The company reported April delivery of 34,000 units, a year-on-year increase of 32% but a month-on-month decrease of 7%. The decline is attributed to the transition between old and new models, with the new MEGA Ultra version expected to boost sales [1][2]. - The upcoming launch of the L series smart refresh is anticipated to drive sales upward, with significant upgrades in technology and features [3]. - The company is positioned to enter a new product cycle with its pure electric series, supported by a solid order performance and an expanding charging infrastructure [4]. Summary by Sections Sales Performance - April sales showed a year-on-year increase of 32%, but a month-on-month decrease of 7%, influenced by the transition of models and inventory clearance [1][2]. - The MEGA Ultra refresh and Home version are expected to enhance product appeal and drive sales post-launch [2]. Product Development - The L series smart refresh is set to launch in May, featuring significant technological upgrades that are likely to boost sales [3]. - The next-generation intelligent driving architecture, VLA model, is expected to enhance user experience and product competitiveness [3]. Financial Projections - The company forecasts net profits of CNY 10.3 billion, CNY 16 billion, and CNY 17.7 billion for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 18.8, 12.1, and 10.9 [4][11]. - Revenue projections indicate a growth trajectory, with expected revenues of CNY 167.3 billion in 2025, increasing to CNY 281.9 billion by 2027 [11][13].

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 263.83 CNY [4][10]. Core Views - The company reported a revenue of 36.726 billion CNY in 2024, representing a year-on-year growth of 5.14%, while the net profit attributable to shareholders was 11.668 billion CNY, a growth of 0.74% [1]. - The first quarter of 2025 showed a revenue of 8.237 billion CNY, a year-on-year decline of 12.12% but a quarter-on-quarter increase of 13.76% [1]. - The recovery in bidding activities since the end of 2024 is expected to gradually improve the company's performance [2]. - The company is positioned as a leader in industry digitalization, leveraging AI to enhance business expansion and innovate its business model [4][9]. Financial Performance Summary - In 2024, the company's revenue from life information and support business was 13.557 billion CNY, down 11.11% year-on-year, while the minimally invasive surgery segment grew over 30% [3]. - The in-vitro diagnostics business generated 13.765 billion CNY in 2024, marking a year-on-year increase of 10.82% [3]. - The medical imaging business achieved a revenue of 7.498 billion CNY in 2024, with international sales growing over 15% [3]. - The company expects revenue growth rates of 10.5%, 15.5%, and 14.6% for 2025 to 2027, respectively, with net profit growth rates of 9.7%, 15.3%, and 15.0% [10].

2025 年 05 月 05 日 生物医药Ⅱ 新药周观点：25Q1 创新药板块持仓环 比大幅提升 本周新药行情回顾： 2025 年 4 月 28 日-2025 年 5 月 2 日，新药板块涨幅前 5 企业：艾迪 药业（19.49%）、科伦博泰生物（17.02%）、乐普生物（16.09%）、 康诺亚（13.61%）、康宁杰瑞（13.60%）；跌幅前 5 企业：康方生物 （-11.22%）、宜明昂科（-10.03%）、东耀药业（-6.90%）、迈博药 业（-6.52%）、亚盛医药（-5.63%）。 本周新药行业重点分析： 根据最新披露的基金 2025 年第一季度报告，我们统计分析了全部所 有基金截止 2025 年 3 月 31 日对于创新药板块的最新重仓持仓情况 （注：在此仅统计了 A 股、港股 Biotech 创新药公司的基金重仓持 仓，对于以恒瑞医药为首的传统转型创新药企业未纳入统计；此外由 于基金季报仅披露重仓持仓情况，因此可能无法完全体现基金对创新 药板块的持仓情况）。 行业周报 证券研究报告 投资评级 领先大市-A 维持评级 | | | 行业表现 资料来源：Wind 资讯 升幅% 1M 3M 12M 相 ...

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 263.83 CNY [4][10]. Core Views - The company reported a revenue of 36.726 billion CNY in 2024, a year-on-year increase of 5.14%, and a net profit of 11.668 billion CNY, up 0.74% year-on-year [1]. - The first quarter of 2025 showed a revenue of 8.237 billion CNY, a year-on-year decrease of 12.12%, but a quarter-on-quarter increase of 13.76% [1]. - The recovery in bidding activities since the end of 2024 is expected to gradually improve the company's performance [2]. - The company is positioned as a leader in industry digitization, leveraging AI to enhance business expansion and innovate its business model [4][9]. Financial Performance Summary - In 2024, the company's revenue from life information and support business was 13.557 billion CNY, a decrease of 11.11%, while the minimally invasive surgery segment grew over 30% [3]. - The in-vitro diagnostics business generated 13.765 billion CNY in 2024, marking a year-on-year growth of 10.82% [3]. - The medical imaging business achieved a revenue of 7.498 billion CNY in 2024, with a growth of 6.60% year-on-year [3]. - The company expects revenue growth rates of 10.5%, 15.5%, and 14.6% for 2025 to 2027, respectively, with net profit growth rates of 9.7%, 15.3%, and 15.0% [10].